Wyeth Pharmaceuticals received approval from the FDA for Pristiq, a structurally novel, once-daily serotonin-norepinephrine reuptake inhibitor (SNRI), to treat adult patients with major depressive disorder (MDD). Wyeth expects to begin shipping the drug to wholesalers in 2Q08.     “We are pleased to be able to bring Pristiq to patients,” says Bernard Poussot, president and chief executive officer of Wyeth. “Pristiq is Wyeth’s fourth new drug to receive approval in the ...